Price T Rowe Associates Inc Fulcrum Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 35,712 shares of FULC stock, worth $162,489. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,712
Previous 35,712
-0.0%
Holding current value
$162,489
Previous $222,000
42.34%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding FULC
# of Institutions
150Shares Held
52.2MCall Options Held
6.91MPut Options Held
1.9M-
Ra Capital Management, L.P. Boston, MA10.2MShares$46.5 Million0.51% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$23.9 Million2.43% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$21.8 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$21.7 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$14.9 Million0.0% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $237M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...